While investors chase semiconductor stocks, the healthcare sector has been sold down to historic lows relative to the S&P 500. Companies like Intuitive Surgical possess unique, valuable proprietary data that AI will leverage, turning these unloved firms into a compelling, long-term AI play.

When evaluating AI startups, don't just consider the current product landscape. Instead, visualize the future state of giants like OpenAI as multi-trillion dollar companies. Their "sphere of influence" will be vast. The best opportunities are "second-order" companies operating in niches these giants are unlikely to touch.

While AI's market performance has been concentrated in the tech sector, its greatest future value will be unlocked as it transforms other industries like healthcare, logistics, and consumer goods. Buchwald believes investors are underestimating this broadening impact, which will create new winners and losers across the entire economy.

While AI holds long-term promise for molecule discovery, its most significant near-term impact in biotech is operational. The key benefits today are faster clinical trial recruitment and more efficient regulatory submissions. The revolutionary science of AI-driven drug design is still in its earliest stages.

While AI is a universal trend, its application is highly contextual. In drug discovery, it's used for complex, high-science tasks like protein folding. In the CDMO space, its value lies in streamlining less glamorous but critical functions like communication, paperwork, and process optimization.

Figma's CEO argues that as capital and talent flock to AI, significant opportunities are being ignored in less-hyped industries. He cites his investments in fintech for farmers and cryogenics as examples of valuable, missionary-led companies thriving outside the crowded AI spotlight.

The AI investment case might be inverted. While tech firms spend trillions on infrastructure with uncertain returns, traditional sector companies (industrials, healthcare) can leverage powerful AI services for a fraction of the cost. They capture a massive 'value gap,' gaining productivity without the huge capital outlay.

While AI for novel drug discovery has lofty goals, its most practical value lies in accelerating development. This includes applying AI to de-risked assets for new indications, improving delivery methods, and designing faster, more effective clinical trials, which is where the real bottleneck lies.

Using the invention of the car as an analogy for AI, the most significant returns often come from second-order effects (e.g., LA real estate, gas stations), not just the core technology (cars/LLMs). Investors should look for these ripple-effect opportunities.